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Abstract Early phase chemoprevention trials differ from standard therapeutic clinical trials because 
asymptomatic, healthy people are treated with a potentially toxic intervention for a prolonged period 
of time. Current subject selection protocols have relied upon epidemiological methods to identify high- 
risk individuals. Most available data provide risk estimates for various individual risk factors, but few 
have reported risk estimates for combinations of risk factors. Selection criteria for the large tamoxifen 
intervention trial (NSABP P1) were developed from the work of Gail et al. 111. The Gail model takes into 
account non-genetic factors (e.g., nulliparity, age at menarche, preexisting pathological conditions) and 
genetic factors (family history). Using a lifetime risk of 10% of developing breast cancer as a standard 
to intervene, NSABP P1 uses the Gail algorithm to select pre- and postmenopausal women for a primary 
intervention trial. This approach has been criticized for being insufficiently selective (i.e., all women 260 
yrs), but appears to be the best available method to select subjects for a chemoprevention trial. Other 
approaches have been based on identification of very high-risk women with acknowledged pathologic 
conditions [lobular carcinoma in situ, ductal carcinoma in situ (DC1S)l. Attempting to use these 
proliferative lesions as pathologic endpoints for drug effect has not been attempted. DCIS as a risk factor 
for tamoxifen intervention was excluded because of controversies over its management and because of 
frequent difficulties in distinguishing microinvasive from non-invasive lesions. Women treated for early 
stage breast cancer (Stage 1) may be subjects for early stage chemopreventive interventions. 
We propose the use of intermediate endpoint biomarkers and genetic markers as entry criteria for 
early phase chemoprevention trials. For colorectal cancer chemoprevention, we have used a two-step 
selection process. The first step was based on epidemiologic risk assessment. Entry into the study 
required that a potential intermediate biomarker be positive and quantifiable. The relationship between 
modulation of a pre-transformational biomarker and development of cancer ultimately needs proof in 
a primary interventional trial; however, this methodology may permit screening of potential 
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chemopreventive agents at lower cost and more rapid turn-around times. In early chemopreventive 
agent testing for breast cancer chemoprevention, we propose a similar two-step procedure. 
Epidemiological and/or pathological criteria for risk would be followed by a procedure to obtain cellular 
material. The cellular material would be assayed for pre-transformational cellular change. 
Identifying predictive genes in familial breast cancer cohorts such as the modified BRCAl gene 
promises to select individuals at high familial and potentially physiological or environmental risk. The 
identification o ie abnormal gene product in individuals and famhes will provide another important 
group of subjects for chemopreventive interventions. The identification of high-risk subjects for breast 
cancer chemoprevention, particularly those with familial genetic risk, carries important ethical problems. 
Such women may have difficulties obtaining health and life insurance, deciding to have children, and 
obtaining work. Chemoprevention trials with genetic selection criteria will need to develop methods of 
dealing with these issues. 
Key words: Breast cancer risk, chemoprevention, intermediate biomarkers 
1 .  Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. (1989) Projecting individualized 
probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer 
Inst 81:1879-1886. 
0 1993 Wiley-Liss, Inc. 
Chemoprevention trials differ in intent and, 
therefore, selection criteria for subjects. Some 
chemoprevention trials are designed to intervene 
in healthy but high-risk populations. In this 
group of subjects, toxicity is intolerable and 
selection criteria revolve around subjects who 
may be genetically or biochemically at higher 
risk than others for developing cancer. Other 
chemoprevention trials are designed to prevent 
recurrence or new primary tumors in previously 
treated cancer patients. In the latter group of 
subjects, some toxicity may be tolerated. In both 
types of trials, selection criteria must be carefully 
defined so that the potential benefits of the inter- 
vention justify the toxicologic risk while ensuring 
that there will be a sufficient pool of subjects to 
achieve the statistical goals of the trial design. 
Selection of subjects for breast cancer chemo- 
prevention is further complicated by problems of 
age (premenopausal versus postmenopausal pop- 
ulations), choice of an appropriate cancer risk 
level for subjects who may require repeated tis- 
sue sampling procedures, exposure to potentially 
toxic drugs, fertility, and the teratogenic risks in 
a child-bearing population, as well as the poten- 
tial genetic and sociological problems with hav- 
ing sufficiently high risk for breast cancer to 
warrant inclusion in a risk-reduction trial at a 
young age. Appropriate chemopreventive doses 
for potential pharmacologic interventions will be 
identified by assessing biochemical or biological 
endpoints in tissue specimens. These Phase I and 
I1 trials will require populations of adherent 
subjects for whom the risk is physically, psycho- 
logically, and ethically acceptable. 
Usual endpoints for cancer clinical trials are 
reduction in tumor size or statistically increased 
survival in populations whose survival is limit- 
ed. Such trials may be completed quickly with 
measurable surrogate (e.g., response of tumor 
mass) or primary endpoints (e.g., survival after a 
new treatment compared with survival after a 
control treatment). Cancer chemoprevention 
trials pose unique problems in clinical trial de- 
sign. For chemopreventive interventions, no such 
easily measured endpoints exist. We must rely 
on events that happen years later, such as the 
development of cancer. Complex biostatistical 
and epidemiological tools are necessary in mas- 
sive study populations in order to prove clinical 
efficacy. Such large trials are expensive and im- 
practical in the process of screening many new, 
promising approaches to chemoprevention. In 
order to simplify and make chemoprevention 
trials cost-effective, the identification of interme- 
diate biomarkers as surrogate endpoints for 
cancer are necessary. Intermediate endpoints will 
play a key role in subject selection criteria for 
future chemoprevention trials. 
To solve the problem of risk identification for 
healthy subjects, many investigators have drawn 
on epidemiologic data that define the risk of 
developing cancer. Quantitative formulas may be 
developed to define epidemiologic and genetic 
risk. Most chemoprevention trials rely upon 
some epidemiologic risk factors as the basis for 
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entry into the study. For early stage chemopre- 
vention trials, the addition of intermediate end- 
points as selection criteria is being tested. Finally, 
genetic risk based on the presence of a known 
genetic marker may be used in the future to 
identify high-risk individuals and their families 
for chemopreventive intervention. We will de- 
scribe approaches to selecting subjects for che- 
moprevention trials drawing on our experience, 
and that of others involved in ongoing chemo- 
prevention trials for high-risk individuals who 
have not yet developed a primary tumor. 
SUBJECTS WITH PRIOR BREAST CANCER 
Patients with locally controlled, low stage 
(Stage I) breast cancer are an attractive pool of 
potential subjects for chemoprevention trials. The 
Milan group [l] has chosen women 1-3 years 
after resection of Stage I (node-negative) breast 
cancer as subjects for Phase I and I1 chemopre- 
vention trials with 4-(hydroxypheny1)retinamide 
(fenretinide, 4-HPR). Such patients have an over- 
all relapse-free survival rate of 70-75% at 10 
years [2,31; however, most recurrences are within 
3 years of initial diagnosis and treatment [4]. 
Chemopreventive interventions in patients with 
225% risk of recurrence may not be feasible 
because precancerous lesions in these patients 
may be too advanced. Selection of women with 
low stage breast cancer for chemopreventive 
intervention may be possible using various mor- 
phologic and biologic indicators of prognosis to 
identify women with a low (<15%) risk of recur- 
rence [51. Such criteria include patients with 
tumors of <1 cm in size, positive steroid recep- 
tors, and a low proliferative rate as characterized 
by flow cytometry. The ultimate goal of chemo- 
preventive intervention in this group of women 
would be the prevention of second primary le- 
sions in either the treated breast or the contralat- 
era1 breast (estimated risk of new primary distal 
from the first primary or in the contralateral 
breast of 1% per year at 5 years) [61. Such wom- 
en might have intermediate biomarker changes 
consistent with a field defect and could be candi- 
dates for early intervention trials. 
BENIGN BREAST DISEASE 
Benign breast disease consists of a heteroge- 
neous group of pathologic changes associated 
with various degrees of breast cancer risk. Breast 
cancer risk is related to proliferative and nonpro- 
liferative conditions [7]. Nonproliferative breast 
disease (e.g., adenosis, fibroadenoma, fibrosis, 
mastitis, mild hyperplasia) is less associated with 
excess risk of breast cancer, whereas the relative 
risk of proliferative breast disease with or with- 
out atypia, is 4.4 [7]. Patients with proliferative 
breast disease and a family history of breast 
cancer have a 20% risk of breast cancer over 15 
years 181 and may benefit from chemopreventive 
interventions. 
Ductal carcinoma in situ (DCIS), a prolifera- 
tion of premalignant epithelial cells confined to 
the mammary ducts, is regarded as a direct pre- 
cursor of cancer and is usually treated surgically. 
The risk of developing invasive breast cancer in 
women who had breast conservation treatment 
for DCIS is 7-10% over 10 years [lo]. The con- 
cept of multicentricity has been recently ques- 
tioned [91. Evidence of unicentricity is less sup- 
portive of a cancer "field effect." Since DCIS 
represents breast cancer at its earliest stage, these 
women are excellent candidates for chemopre- 
ventive interventions using biomarker analysis to 
estimate the potential for recurrence or primary 
breast cancer. 
A significant body of data supports the hy- 
pothesis that LCIS is a marker for increased 
cancer risk in either breast [11,12]. This group of 
patients may also be excellent for all phases of 
chemoprevention trials. 
SELECTION OF SUBJECTS WITHOUT PRIOR 
BREASTCANCER 
Epidemiologic Selection Criteria 
Data from studies of millions of women devel- 
oping breast cancer provide some insight into the 
risk of developing breast cancer. Numerous 
studies have consistently found gender, age, 
family history, presence of histologic precursor 
lesions, early age at menarche, late age at meno- 
pause, low parity, older age at first birth, history 
of a previous breast cancer, and radiation expo- 
sure to be factors influencing an individual's risk 
of breast cancer [13-191. Risk factors can be pres- 
ent separately or in an infinite number of combi- 
nations. The direct approach to estimating the 
absolute probability of developing breast cancer 
for each risk factor separately or in combination 
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is not feasible. Given the available data, the best 
method is to use epidemiologic models. 
Epidemiologic Models for Selection Criteria 
in Chemoprevention Trials 
Several attempts have been made to devise 
population-based selection strategies for breast 
cancer screening [20-261 or estimates of absolute 
breast cancer risk [17,27,281. The population- 
based selection strategies have some common 
weaknesses. For example, Soini and colleagues 
[24] constructed a multivariate discriminant 
which correctly identified 85% of cases as being 
high risk, but also included the majority (65%) of 
heal thy controls in this high-risk classification. 
Alexander and colleagues [21] used four risk 
factors to define a high-risk subgroup of 48% of 
women, but it identified only 56% of all the 
breast cancers. For cancer screening, most would 
agree that the sensitivity of any selection proto- 
col should not fall below 80-90%, otherwise the 
intent of screening would be nullified. The same 
requirements can be used for selection criteria 
for chemoprevention trials. Studies by Ottman 
and Anderson [27,28] focused on relatives of 
women with known breast cancer. This unique 
population does not consider the vast number of 
women without family history of breast cancer 
or other risk factors. 
Gail and colleagues [17] developed a model 
based on 5,998 participants in the Breast Cancer 
Detection Demonstration Project (BCDDP), to 
estimate the long-term probability that a woman 
with a specified combination of risk factors 
would develop breast cancer. The risk factors 
identified were age, age at menarche, age at first 
live birth, the number of previous breast biop- 
sies, and the number of first-degree relatives 
with breast cancer. This model is being used as 
the selection criteria for the National Surgical 
Adjuvant Breast and Bowel Project (NSABP P1) 
trial, setting the minimum relative risk for entry 
as 10% lifetime risk. Some potential limitations of 
this model are the possible overestimation of 
relative risk due to self-selection of women into 
the BCDDP program, and the total focus on 
Caucasian women. The M.D. Anderson group 
has recently tested the Gail model using SEER 
data and found it to be predictive of breast can- 
cer risk [29]. This model represents the best one 
available combining genetic and biological risk 
factors. 
Intermediate Biomarkers in 
Chemoprevention Trials 
Regardless of the approach used to identify 
high-risk women for breast cancer chemopreven- 
tion studies, one is left with the difficult task of 
using endpoints such as diagnosis of invasive 
breast cancer or death from breast cancer. This 
creates logistical problems with respect to the 
research design (e.g., 16,000 women in the 
NSABP Pl), many years of intervention and 
follow-up, and massive resources. 
Since cancer is an uncommon event and the 
duration of time until sufficient subjects develop 
cancer is long, it is not feasible to perform such 
an observational trial for the many potential 
chemopreventive compounds becoming available 
for clinical trial. Modulation of markers of pre- 
malignant cells from individuals at risk reduces 
the size of population and the time required for 
study. 
The optimal intermediate biological endpoint 
for an at-risk population will be readily ex- 
pressed in tissues that are accessible to biopsy or 
in the plasma, related in some way to the pro- 
cesses of neoplastic transformation and progres- 
sion, easily measured from small quantities of 
tissue, quantifiable as a continuous variable, and 
expected to be modulated by chemopreventive 
intervention. 
To determine chemopreventive efficacy, we 
propose the use of drug effect, biological, and 
pathological endpoints. We define a drug effect 
endpoint as one in which a pharmacologic agent 
modulates a cell's normal biochemical function. 
For example, in determining aspirin's chemopre- 
ventive effects on colorectal mucosa, we first 
need to determine whether sufficient drug has 
reached the appropriate cells to modulate cellu- 
lar function. Assessment of cyclooxygenase activ- 
ity through the amount of prostaglandin product 
in gut tissue constitutes a drug effect endpoint, 
because it measures a known biochemical target 
of drug action. Measuring drug effect tells us 
that the dose and schedule of a potential chemo- 
preventive agent is delivered in sufficient 
amounts to the target site to cause an effect. This 
concept is useful in Phase I and I1 chemopreven- 
tion trials. 
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We define a biological endpoint as one in 
which an intervention changes a cellular product 
which has been identified as a marker for cancer 
risk. For example, a change in the expression of 
the oncogene product p21 is such an endpoint. 
We define a pathological endpoint as one in 
which a defined premalignant lesion, such as 
cervical intraepithelial neoplasia, measured visu- 
ally using colposcopy and pathologically by 
biopsy, reverses after a defined treatment period. 
Such endpoints are directly on the causal path- 
way to cancer. As such, pathological endpoints 
may be used to measure the effects of chemo- 
preventive agents [30, these proceedings] and 
identify cohorts for chemoprevention trials. 
Combined Epidemiologic and Intermediate 
Biomarker Subject Selection Criteria 
Phase I1 chemoprevention trials are designed 
to determine if a potential chemopreventive 
agent will modulate a biological endpoint as a 
surrogate for chemopreventive effect. Phase IIa 
trials identify optimal doses of a putative chemo- 
preventive agent that modulate biological inter- 
mediate endpoints through a dose escalation 
schema, while Phase IIb trials identify the activi- 
ty of a given chemopreventive agent through 
modulation of an intermediate endpoint in a 
randomized trial. 
Because the goal of Phase I1 chemoprevention 
trials is modulating an intermediate biomarker, 
we have required a two-step subject selection 
process. The first step requires sufficiently high 
epidemiologic risk to provide motivated subjects. 
The second step requires an intermediate end- 
point assay of a biological specimen. Results of 
the assay should be in the "high risk' range as 
determined by prior evaluation of the test. By 
"frontloading" our Phase I1 trials with a popula- 
tion of subjects who have known changes in a 
surrogate endpoint, the potential efficacy of a 
chemopreventive drug may be rapidly tested in 
a human population. 
Such a two-step approach reduces the power 
requirements necessary to demonstrate a biologi- 
cal change in a cohort of subjects in whom the 
marker is already theoretically outside the nor- 
mal population distribution. By attempting to 
control for large biological variability and using 
a paired study design wherein each subject 
serves as her own control, a reduction in the 
study sample size simplifies the two-step design 
approach. 
The two-step design adds complexity to the 
on-study stage of a chemoprevention trial-each 
potential experimental subject must provide a 
specimen for assay prior to study entry. This 
process increases the time required for study 
entry, and reduces the overall efficiency of study 
execution. Not all subjects who are epidemiologi- 
cally suitable will have an appropriately altered 
biological intermediate endpoint for study entry. 
More samples will need to be processed than the 
numbers of subjects actually entering the trial. 
The ratio of specimens versus subjects entering 
the trial will depend on the rigidity of the epide- 
miological selection criteria and the assay entry 
requirements. Cost savings are realized by the 
smaller numbers of subjects needed to meet 
power requirements. 
Genetic Selection Criteria 
While the contribution of family history to the 
risk of developing breast cancer has been careful- 
ly studied epidemiologically [15,17,18,22,231, the 
recent work of King et al. 131,321 identified chro- 
mosome 17q12-21 as the location of a gene alter- 
ation responsible for the development of breast 
cancer and ovarian cancer by genetic linkage 
analysis. This gene, which has not been cloned 
and sequenced to date, is now termed BRCA1. 
Families with breast and ovarian carcinoma that 
are thought to have resulted from BRCAl muta- 
tions have been identified by many groups, and 
some investigators have begun to provide fami- 
lies with information on mutation carrier status 
[33]. Female carriers of altered BRCAl are esti- 
mated to have an 85% lifetime risk of developing 
breast or ovarian cancer or both. More than 50% 
of the breast cancers occur prior to age 50. Inher- 
itance follows classical Mendelian autosomal 
dominant inheritance patterns [34,35]. Inherited 
BRCAl germline mutations may account for 
2-10% of all breast cancer. Somatically acquired 
mutations of BRCAl or other key loci on chro- 
mosome 17 may account for some sporadic cases 
of breast cancer [36]. 
The Li-Fraumeni syndrome is a rare familial 
cancer syndrome resulting from an inherited 
mutant p53 allele. Inherited mutations in p53 
may account for about 1% of breast cancer 
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among patients who are diagnosed before age 40 
1371. An altered estrogen receptor (ER) gene may 
be responsible for inherited breast cancer. One 
description of a family with postmenopausal 
breast cancer linked to ER has been published 
[%I. 
When the BRCAl sequence is known, it will 
be possible to identify women who carry the 
high-risk allele. Such women would become 
candidates for chemopreventive intervention. 
Currently, women with linkage studies and fami- 
ly histories that support altered BRCAl inheri- 
tance have undergone bilateral mastectomies and 
oophorectomies in the hope of preventing can- 
cers at these sites. Once the function and product 
of this gene is determined, gene therapy, as well 
as chemopreventive intervention, may be a possi- 
ble treatment for these women. 
Of perhaps greater importance is the descrip- 
tion of a gene in which acquired somatic muta- 
tions may lead to early risk of developing spon- 
taneous, noninherited breast cancer. Since 90% of 
breast cancer cases are spontaneous, the develop- 
ment of pre-transformational genetic markers 
such as altered BRCAl may be used in future 
chemoprevention trials as selection criteria. Opti- 
mally, genetic mutations used for subject selec- 
tion for chemoprevention trials should be suffi- 
ciently early in carcinogenesis that cells are mor- 
phologically normal. yet genetically abnormal. 
Spontaneous BRCAl mutations, or other poten- 
tial genetic markers (e.g., ER), have the potential 
for being key selection criteria for chemopreven- 
tion subjects, as well as identifying pharmacolog- 
ic or genetic materials that might be used to 
reverse the transformation process. 
ETHICAL CONSIDERATIONS 
Psychosocial and Economic Issues 
The psychological, social, reproductive, and 
economic consequences of having sufficient risk 
to be selected into chemoprevention trials need 
careful attention and planning. For example, 
what are the reproductive consequences in pre- 
menopausal women who desire children and 
carry the high-risk BRCAl allele? Will such a 
woman be able to obtain health insurance in our 
current system given her genetic "diagnosis"? 
How and when should such information be 
disclosed to the patient? To her employers? To 
her family? Will participation in a chemopreven- 
tion trial impair a women's ability to obtain 
employment? Will affected women have difficul- 
ties establishing strong, lasting emotional and 
sexual relationships? 
As molecular epidemiology becomes the basis 
for chemoprevention trial subject selection, we 
must deal with the ethical consequences of our 
selection process. The Breast Cancer Center at 
the University of Michigan has developed a 
protocol to address the many issues that arise 
with molecular diagnosis [391. First, precoun- 
seling education and assessment occurs several 
weeks prior to the planned clinic visit. At this 
session, a genetic counselor and oncology nurse 
obtain informed consent and draw blood sam- 
ples for genetic testing. Risks and benefits of 
learning molecular risk status are presented in 
order to permit subjects to make informed deci- 
sions about receiving test results. Risks including 
jeopardizing insurance coverage, the possibility 
of expensive surgery, disclosure to employers or 
potential employers, and confidentiality among 
other family members are thoroughly discussed. 
Second, results are disclosed by a multidisci- 
plinary team including geneticists, oncologists, 
genetic counselors, and oncology nurses. The 
team educates subjects (both gene carriers and 
noncarriers) about the methods used to detect a 
genetic defect, explains the test results, discusses 
future risks for breast cancer, explains medical 
interventions, chemoprevention or screening 
options, and provides psychological support 
options. Third, members of the breast care team 
and other mental health professionals provide 
psychological support. There is ample opportuni- 
ty to discuss emotional responses, and follow-up 
counseling is provided. Finally, social issues are 
addressed. The University of Michigan Group 
has opted not to reveal results to individuals 
younger than 18 years of age because there are 
no known medical benefits to a minor knowing 
that he or she is a gene carrier. It is difficult to 
determine the emotional maturity required to 
receive such results. There are no nationally 
established guidelines for screening minors for 
late-onset disorders. The potential risks of loss of 
insurance are discussed with each family at 
length. A separate shadow file for each patient is 
established so that the results of genetic testing 
are not reflected in the hospital chart. 
240 Ruffin et al. 
Chemopreventives as Potential Teratogens 
in Women of Reproductive Age 
Pharmacologic chemopreventives may have 
known or unknown teratogenic potential. The 
problem is especially important when chemopre- 
ventive interventions are contemplated in wom- 
en of reproductive age. We wish to select women 
with high-risk breast lesions or who carry gene 
muta IS associated with inherited breast cancer 
for chemoprevention trials. We have supported 
entry of premenopausal women into chemopre- 
vention trials using compounds that are potential 
teratogens (eg. ,  retinoids) for the following rea- 
sons: (1) Early stage or high-risk breast lesions 
are usually discovered in women of reproductive 
age. We are concerned that, by studying only 
postmenopausal women, we will select a subset 
of women who have a different level of risk, and 
perhaps, different mechanisms of pre-transforma- 
tional change from premenopausal women. (2) 
Many Phase I1 chemoprevention trials are 12 
months or less in duration. We feel it is reason- 
able to demand hormonal methods of birth con- 
trol for the period of study in premenopausal 
women. The potential effects of hormonal birth 
control on breast cellular precancer events 
should be controlled for in a trial design in 
which the placebo arm consists of women on 
hormonal birth control and a placebo chemopre- 
ventive. While we would prefer to include a 
barrier method of birth control in our design, we 
feel that inclusion of such methods will require 
additional stratification and increase the com- 
plexity and costs of chemoprevention trials. The 
loss of potential subject accruals due to rejection 
of hormonal birth control methods would, in our 
estimation, be minimal. 
SUMMARY 
Selection of subjects for interventional chemo- 
prevention trials is currently based on epidemio- 
logical criteria. We have proposed a two-step 
entry procedure that includes an epidemiologic 
risk assessment followed by demonstration of an 
intermediate biomarker that may be used as a 
surrogate endpoint in chemoprevention trials. 
The development of reproducible molecular 
diagnostic methods will revolutionize entry crite- 
ria for chemoprevention trials by identifying 
young, high-risk subjects. Identification of abnor- 
mal genetic products in women with familial 
breast cancer is an example. Such information 
may be used to detect precancerous cellular 
changes in women who will develop spontane- 
ous breast cancer, thus providing more precise 
selection criteria for chemopreventive interven- 
tions. 
In a time of turmoil in our medical care sys- 
tem and a new emphasis on preventing deadly 
diseases such as breast cancer, we must ensure 
that our subjects do not suffer unnecessarily 
from the psychological, social, and economic 
consequences of their gene tic inheritance. 
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